Xiaoqi Liu Selected Research

Prostatic Neoplasms (Prostate Cancer)

4/2022	A single arm phase II study of bone-targeted Sn-117 m-DTPA in symptomatic castration-resistant prostate cancer with skeletal metastases.
1/2022	Peroxiredoxin IV plays a critical role in cancer cell growth and radioresistance through the activation of the Akt/GSK3 signaling pathways.
1/2022	Targeting DNMTs to Overcome Enzalutamide Resistance in Prostate Cancer.
1/2022	Diptoindonesin G antagonizes AR signaling and enhances the efficacy of antiandrogen therapy in prostate cancer.
1/2021	Co-Targeting Plk1 and DNMT3a in Advanced Prostate Cancer.
12/2020	Inhibition of EZH2 Enhances the Antitumor Efficacy of Metformin in Prostate Cancer.
1/2020	Inhibition of the erythropoietin-producing receptor EPHB4 antagonizes androgen receptor overexpression and reduces enzalutamide resistance.
1/2020	p300/CBP inhibition enhances the efficacy of programmed death-ligand 1 blockade treatment in prostate cancer.
1/2020	Inhibition of noncanonical Wnt pathway overcomes enzalutamide resistance in castration-resistant prostate cancer.
1/2019	NOTCH signaling is activated in and contributes to resistance in enzalutamide-resistant prostate cancer cells.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Xiaoqi Liu Research Topics

Disease

48	Neoplasms (Cancer) 01/2022 - 05/2003
30	Prostatic Neoplasms (Prostate Cancer) 04/2022 - 10/2011
8	Myopia 01/2019 - 06/2011
7	Neoplasm Metastasis (Metastasis) 04/2022 - 09/2008
6	Carcinogenesis 01/2022 - 07/2009
6	Inflammation (Inflammations) 01/2022 - 12/2014
3	Pancreatic Neoplasms (Pancreatic Cancer) 01/2020 - 01/2013
3	Hypoxia (Hypoxemia) 01/2019 - 08/2012
3	Insulin Resistance 01/2018 - 08/2014
3	Obesity 01/2018 - 08/2014
3	Melanoma (Melanoma, Malignant) 01/2018 - 04/2016
2	Pain (Aches) 04/2022 - 01/2022
2	COVID-19 01/2021 - 01/2020
2	Type 2 Diabetes Mellitus (MODY) 12/2020 - 01/2014
2	Adenocarcinoma 01/2020 - 01/2016
2	Kashin-Beck Disease 01/2013 - 11/2011
2	Macular Degeneration (Age-Related Maculopathy) 09/2010 - 01/2010
1	Infections 01/2022
1	Osteosarcoma (Osteogenic Sarcoma) 01/2022
1	Corneal Injuries 01/2022
1	Bone Resorption 11/2021
1	Osteoporosis 11/2021
1	Colorectal Neoplasms (Colorectal Cancer) 10/2021
1	Pathologic Constriction (Stenosis) 07/2021
1	Dyslipidemias (Dyslipidemia) 01/2021
1	Hyperlipidemias (Hyperlipidemia) 01/2021
1	Renal Cell Carcinoma (Grawitz Tumor) 01/2021

Drug/Important Bio-Agent (IBA)

20	Polo-Like Kinase 1IBA 01/2018 - 09/2003
14	Androgen Receptors (Androgen Receptor)IBA 01/2022 - 09/2013
14	Proteins (Proteins, Gene)FDA Link 10/2021 - 09/2010
13	Pharmaceutical PreparationsIBA 01/2022 - 01/2013
10	enzalutamideIBA 01/2022 - 01/2016
8	AndrogensIBA 01/2022 - 09/2013
6	Phosphotransferases (Kinase)IBA 01/2022 - 05/2003
4	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 09/2010
4	Small Interfering RNA (siRNA)IBA 01/2022 - 05/2003
4	EnzymesIBA 01/2022 - 11/2014
4	BI 2536IBA 10/2021 - 01/2015
4	RNA (Ribonucleic Acid)IBA 01/2021 - 01/2019
4	Metformin (Glucophage)FDA LinkGeneric 12/2020 - 01/2014
4	Antineoplastic Agents (Antineoplastics)IBA 12/2020 - 01/2015
4	CholesterolIBA 01/2018 - 03/2014
3	Androgen Antagonists (Antiandrogens)IBA 01/2022 - 01/2018
3	Biomarkers (Surrogate Marker)IBA 01/2022 - 10/2017
3	LipidsIBA 01/2021 - 08/2014
3	Messenger RNA (mRNA)IBA 01/2021 - 09/2008
3	Transcription Factors (Transcription Factor)IBA 01/2019 - 06/2011
3	CateninsIBA 01/2018 - 12/2015
3	Cholesterol Esters (Cholesteryl Esters)IBA 01/2018 - 03/2014
3	Biological ProductsIBA 10/2017 - 01/2014
2	MethyltransferasesIBA 01/2022 - 12/2020
2	Aggrecans (Aggrecan)IBA 01/2020 - 06/2014
2	Blood Glucose (Blood Sugar)IBA 01/2018 - 08/2014
2	Insulin (Novolin)FDA Link 01/2018 - 01/2015
2	SirtuinsIBA 01/2018 - 04/2016
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2018 - 11/2013
2	Insulin-Like PeptidesIBA 03/2017 - 01/2015
2	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2017 - 01/2017
2	BI 6727IBA 01/2017 - 06/2015
2	olaparibIBA 01/2017 - 01/2017
2	TensinsIBA 11/2016 - 10/2011
2	Phosphoric Monoester Hydrolases (Phosphatases)IBA 11/2016 - 10/2014
2	Glucose (Dextrose)FDA LinkGeneric 01/2016 - 08/2014
2	Gemcitabine FDA Link 01/2016 - 01/2013
2	IodineIBA 01/2013 - 11/2011
2	SeleniumIBA 01/2013 - 11/2011
1	Testosterone (Sustanon)FDA Link 04/2022
1	Radioisotopes (Radionuclides)IBA 04/2022
1	Pentetic Acid (DTPA)FDA LinkGeneric 04/2022
1	Radium-223IBA 04/2022
1	RadiopharmaceuticalsIBA 04/2022
1	PeroxiredoxinsIBA 01/2022
1	baicalinIBA 01/2022
1	diptoindonesin GIBA 01/2022
1	Decitabine FDA Link 01/2022
1	Alpha-Ketoglutarate-Dependent Dioxygenase FTOIBA 11/2021
1	NF-kappa B (NF-kB)IBA 11/2021
1	indoleIBA 10/2021
1	QuinolinesIBA 10/2021
1	Adenosine Monophosphate (AMP)IBA 10/2021
1	quinolineIBA 10/2021
1	AntigensIBA 01/2021
1	Therapeutic UsesIBA 01/2021
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2021
1	Ribosomal DNA (rDNA)IBA 01/2021
1	LigandsIBA 01/2021
1	InterferonsIBA 01/2021
1	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 01/2021
1	Small Cytoplasmic RNAIBA 01/2021

Therapy/Procedure

21	Therapeutics 04/2022 - 05/2003
15	Castration 04/2022 - 11/2014
2	Contact Lenses 01/2022 - 05/2018
2	Drug Therapy (Chemotherapy) 10/2021 - 01/2016
1	Precision Medicine 04/2022
1	Gamma Cameras (Gamma Camera) 04/2022
1	Radiotherapy 01/2022
1	Immunotherapy 10/2021
1	Decompression 07/2021
1	Laminoplasty 07/2021
1	Nephrectomy 01/2021